Medpace Holdings, Inc.

NasdaqGS:MEDP Stok Raporu

Piyasa değeri: US$9.9b

Medpace Holdings Yönetim

Yönetim kriter kontrolleri 4/4

Medpace Holdings' CEO is August Troendle, appointed in Jul 1992, has a tenure of 32.33 years. total yearly compensation is $1.65M, comprised of 49.5% salary and 50.5% bonuses, including company stock and options. directly owns 17.37% of the company’s shares, worth $1.72B. The average tenure of the management team and the board of directors is 5.8 years and 6.3 years respectively.

Anahtar bilgiler

August Troendle

İcra Kurulu Başkanı

US$1.6m

Toplam tazminat

CEO maaş yüzdesi49.5%
CEO görev süresi32.3yrs
CEO sahipliği17.4%
Yönetim ortalama görev süresi5.8yrs
Yönetim Kurulu ortalama görev süresi6.3yrs

Son yönetim güncellemeleri

Recent updates

Medpace: Buy The Short-Term Pain For Long-Term Gains

Oct 26

Why Medpace Holdings Is A 'Better Mousetrap'

Oct 16

Medpace Holdings, Inc.'s (NASDAQ:MEDP) Earnings Haven't Escaped The Attention Of Investors

Sep 19
Medpace Holdings, Inc.'s (NASDAQ:MEDP) Earnings Haven't Escaped The Attention Of Investors

Should You Be Adding Medpace Holdings (NASDAQ:MEDP) To Your Watchlist Today?

Sep 02
Should You Be Adding Medpace Holdings (NASDAQ:MEDP) To Your Watchlist Today?

Medpace: Continued Business Growth With Asymmetrical Payoff Opportunity

Aug 20

Why Medpace Holdings' (NASDAQ:MEDP) Earnings Are Better Than They Seem

Jul 31
Why Medpace Holdings' (NASDAQ:MEDP) Earnings Are Better Than They Seem

Medpace Holdings, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Jul 25
Medpace Holdings, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

What You Can Learn From Medpace Holdings, Inc.'s (NASDAQ:MEDP) P/E

Jun 18
What You Can Learn From Medpace Holdings, Inc.'s (NASDAQ:MEDP) P/E

Medpace: Clear Winner If China Blockade Succeeds

Jun 04

A Look At The Fair Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)

May 22
A Look At The Fair Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)

Does Medpace Holdings (NASDAQ:MEDP) Deserve A Spot On Your Watchlist?

Apr 12
Does Medpace Holdings (NASDAQ:MEDP) Deserve A Spot On Your Watchlist?

Medpace: Exceptional Performance, Almost Fully Priced In

Mar 11

Medpace Holdings, Inc.'s (NASDAQ:MEDP) 32% Jump Shows Its Popularity With Investors

Feb 18
Medpace Holdings, Inc.'s (NASDAQ:MEDP) 32% Jump Shows Its Popularity With Investors

Should You Think About Buying Medpace Holdings, Inc. (NASDAQ:MEDP) Now?

Feb 09
Should You Think About Buying Medpace Holdings, Inc. (NASDAQ:MEDP) Now?

A Look At The Intrinsic Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)

Jan 25
A Look At The Intrinsic Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)

Should You Be Adding Medpace Holdings (NASDAQ:MEDP) To Your Watchlist Today?

Jan 10
Should You Be Adding Medpace Holdings (NASDAQ:MEDP) To Your Watchlist Today?

Shareholders Should Be Pleased With Medpace Holdings, Inc.'s (NASDAQ:MEDP) Price

Dec 26
Shareholders Should Be Pleased With Medpace Holdings, Inc.'s (NASDAQ:MEDP) Price

Should You Investigate Medpace Holdings, Inc. (NASDAQ:MEDP) At US$275?

Nov 08
Should You Investigate Medpace Holdings, Inc. (NASDAQ:MEDP) At US$275?

Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Could Be 29% Below Their Intrinsic Value Estimate

Oct 23
Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Could Be 29% Below Their Intrinsic Value Estimate

If EPS Growth Is Important To You, Medpace Holdings (NASDAQ:MEDP) Presents An Opportunity

Oct 10
If EPS Growth Is Important To You, Medpace Holdings (NASDAQ:MEDP) Presents An Opportunity

Does Medpace Holdings (NASDAQ:MEDP) Have A Healthy Balance Sheet?

Aug 27
Does Medpace Holdings (NASDAQ:MEDP) Have A Healthy Balance Sheet?

Should You Think About Buying Medpace Holdings, Inc. (NASDAQ:MEDP) Now?

Jul 31
Should You Think About Buying Medpace Holdings, Inc. (NASDAQ:MEDP) Now?

A Look At The Fair Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)

Jul 18
A Look At The Fair Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)

Here's Why We Think Medpace Holdings (NASDAQ:MEDP) Might Deserve Your Attention Today

Jul 04
Here's Why We Think Medpace Holdings (NASDAQ:MEDP) Might Deserve Your Attention Today

Is Medpace Holdings (NASDAQ:MEDP) A Risky Investment?

May 25
Is Medpace Holdings (NASDAQ:MEDP) A Risky Investment?

Is Now The Time To Look At Buying Medpace Holdings, Inc. (NASDAQ:MEDP)?

Apr 27
Is Now The Time To Look At Buying Medpace Holdings, Inc. (NASDAQ:MEDP)?

An Intrinsic Calculation For Medpace Holdings, Inc. (NASDAQ:MEDP) Suggests It's 28% Undervalued

Apr 12
An Intrinsic Calculation For Medpace Holdings, Inc. (NASDAQ:MEDP) Suggests It's 28% Undervalued

We Ran A Stock Scan For Earnings Growth And Medpace Holdings (NASDAQ:MEDP) Passed With Ease

Mar 27
We Ran A Stock Scan For Earnings Growth And Medpace Holdings (NASDAQ:MEDP) Passed With Ease

Does Medpace Holdings (NASDAQ:MEDP) Have A Healthy Balance Sheet?

Feb 14
Does Medpace Holdings (NASDAQ:MEDP) Have A Healthy Balance Sheet?

What Is Medpace Holdings, Inc.'s (NASDAQ:MEDP) Share Price Doing?

Jan 16
What Is Medpace Holdings, Inc.'s (NASDAQ:MEDP) Share Price Doing?

Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Could Be 41% Below Their Intrinsic Value Estimate

Jan 03
Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Could Be 41% Below Their Intrinsic Value Estimate

Here's Why We Think Medpace Holdings (NASDAQ:MEDP) Might Deserve Your Attention Today

Dec 20
Here's Why We Think Medpace Holdings (NASDAQ:MEDP) Might Deserve Your Attention Today

Medpace Holdings (NASDAQ:MEDP) Has A Rock Solid Balance Sheet

Nov 16
Medpace Holdings (NASDAQ:MEDP) Has A Rock Solid Balance Sheet

Growth Investors: Industry Analysts Just Upgraded Their Medpace Holdings, Inc. (NASDAQ:MEDP) Revenue Forecasts By 13%

Nov 03
Growth Investors: Industry Analysts Just Upgraded Their Medpace Holdings, Inc. (NASDAQ:MEDP) Revenue Forecasts By 13%

CEO Tazminat Analizi

August Troendle'un ücretlendirmesi Medpace Holdings'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

US$366m

Jun 30 2024n/an/a

US$340m

Mar 31 2024n/an/a

US$312m

Dec 31 2023US$2mUS$814k

US$283m

Sep 30 2023n/an/a

US$273m

Jun 30 2023n/an/a

US$268m

Mar 31 2023n/an/a

US$257m

Dec 31 2022US$2mUS$770k

US$245m

Sep 30 2022n/an/a

US$227m

Jun 30 2022n/an/a

US$209m

Mar 31 2022n/an/a

US$199m

Dec 31 2021US$6mUS$697k

US$181m

Sep 30 2021n/an/a

US$182m

Jun 30 2021n/an/a

US$175m

Mar 31 2021n/an/a

US$159m

Dec 31 2020US$4mUS$608k

US$145m

Sep 30 2020n/an/a

US$124m

Jun 30 2020n/an/a

US$107m

Mar 31 2020n/an/a

US$110m

Dec 31 2019US$8mUS$504k

US$100m

Sep 30 2019n/an/a

US$93m

Jun 30 2019n/an/a

US$88m

Mar 31 2019n/an/a

US$78m

Dec 31 2018US$528kUS$420k

US$73m

Sep 30 2018n/an/a

US$61m

Jun 30 2018n/an/a

US$52m

Mar 31 2018n/an/a

US$45m

Dec 31 2017US$598kUS$419k

US$39m

Tazminat ve Piyasa: August's total compensation ($USD1.65M) is below average for companies of similar size in the US market ($USD12.87M).

Tazminat ve Kazançlar: August's compensation has been consistent with company performance over the past year.


CEO

August Troendle (68 yo)

32.3yrs

Görev süresi

US$1,646,031

Tazminat

Dr. August James Troendle, M.D. serves as Chairman of CinRx Pharma, LLC. He has been the Chairman, Chief Executive Officer at Medpace Holdings, Inc. since July 1992 and served as its President since July 1...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
August Troendle
Chairman & CEO32.3yrsUS$1.65m17.37%
$ 1.7b
Jesse Geiger
President3.3yrsUS$945.08k0.069%
$ 6.9m
Kevin Brady
CFO & Treasurer5.8yrsUS$690.48k0.019%
$ 1.9m
Susan Burwig
Executive Vice President of Operations7.8yrsUS$1.12m0.19%
$ 18.4m
Stephen Ewald
Chief Compliance Officer12.4yrsUS$914.64k0.043%
$ 4.3m
Brandon Ebken
Chief Information Officer3.8yrsVeri yokVeri yok
Lauren Morris
Associate Director of Investors Relationsno dataVeri yokVeri yok
Todd Meyers
Vice President of Business Development & Marketingno dataVeri yokVeri yok
John Wynne
Senior Vice President of Commercial Operations & Clinical Pharmacology Unitno dataVeri yokVeri yok
Reinilde Heyrman
Chief Medical Officer of Medical Department1.8yrsVeri yokVeri yok
Gina Leisring
Senior Vice President of Clinical Monitoringno dataVeri yokVeri yok

5.8yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: MEDP's management team is seasoned and experienced (5.8 years average tenure).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
August Troendle
Chairman & CEO32.3yrsUS$1.65m17.37%
$ 1.7b
Fred Davenport
Lead Independent Director6.3yrsUS$264.98k0.0065%
$ 639.2k
Cornelius McCarthy
Independent Director6.3yrsUS$217.48k0.017%
$ 1.7m
Robert Kraft
Independent Director8.3yrsUS$227.35k0.0019%
$ 189.3k
Brian Carley
Independent Director8.3yrsUS$234.97k0.070%
$ 7.0m
Femida Gwadry-Sridhar
Independent Director1.8yrsUS$258.37k0%
$ 0
Dani Zander
Directorless than a yearVeri yokVeri yok

6.3yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: MEDP's board of directors are considered experienced (6.3 years average tenure).